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Abstract
THE ISOLATION AND CHARACTERIZATION OF GROWTH REGULATORY FACTORS PRODUCED
BY A HERPES SIMPLEX VIRUS TYPE 2 TRANSFORMED MOUSE TUMOR CELL LINE, H238
by
Robert B. Stagg
Transformation of cells with herpes simplex virus Type 2 (HSV-
2)occurs by an unknown mechanism. No specific gene or gene product has
been consistently associated with HSV-2 transformation as is the case
This study was performed in an attempt tofor other tumor viruses.
associate HSV-2-transformation with specific growth factors in order to
develop a testable model for HSV-2-transformation. For some tumor
viruses, particularly those containing RNA, there has been a central
concept (autocrine secretion) linking oncogenes and growth factors. This
concept centers on the ability of the cancer cells to produce and
We report here the isolationrespond to their own autologous factors.
and characterization of four growth regulatory factors produced by H238,
an HSV-2-transformed mouse tumor cell line.
The H238 cells were grown in culture flasks to two-thirds confluency
in medium containing 10% fetal bovine serum. The medium was removed, the
cells were washed and medium without serum was added to the cells. At
this conditioned medium (H238-CM), whichintervals of 48 hours,
contained growth regulatory factors, produced by the cells, was
These factors were separated from thewithdrawn and stored frozen.
H238-CM by heparin-sepharose affinity chromatography into three peaks of
mitogenic activity and a fourth containing inhibitory activity for
The three peaks of mitogenic activity have been identifiedsplenocytes.
based on physiochemical characteristics: the first supported the
anchorage-independent growth of EGF treated NRK-c-49 cells and resembles
transforming growth factor-^ (TGF-/3); the second bound to lectin-coated
sepharose beads and was sensitive to trypsin, neuroaminidase, and the
resembled a platelet-derivedreducing agent dithiothreitol (DTT) and,
125I]-labeledgrowth factor (PDGF)-like factor; and the third displaced [
basic fibroblast growth factor (bFGF) in a dose dependent fashion when
The fourth peak was inhibitorytested with a radioimmune assay (RIA).
for a variety of splenocyte function assays. It inhibited lectin-
induced blastogenesis, allogenic mixed lymphocyte reaction (MLR), and
It appeared to act on splenocyte Gq/G-^ 
transition causing growth arrest by inhibiting c-myc proto-oncogene
IL-2 production by splenocytes.
A model for the interaction of these factors in vivo isexpression.
presented with an emphasis on testability.
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The Isolation and Characterization of Growth Regulatory Factors Produced 
by a Herpes Simplex Virus Type 2 Transformed Mouse Tumor Cell Line, H238
Introduction
The H238 tumor cell line (1) is an embryonic fibroblast of BALB/c
origin transformed in vitro by infection with ultraviolet lightmouse
(UV)-irradiated herpes simplex virus Type-2 (strain Savage; HSV-2).
Oncogenic potential of the cell line has been established in many dose-
response experiments (1,2).
£
1 x 10 cells are injected subcutaneously into syngeneic hosts.
A 100% incidence of tumors is produced when
We have
studied the host's response to the tumor challenge and the dietary
During these studies we havemodification of this response (2-5).
observed specific instances where the tumor cell apparently affects its
ability to form tumors by the production of growth regulatoryown
The in vitro inhibition of spleen cell proliferation (6) andfactors.
colony formation in soft agar (1 and unpublished observation in our
laboratory) and in vivo angiogenesis (unpublished observation in our
laboratory) are H238 tumor characteristics believed to be under the
In experiments described in thiscontrol of growth regulatory factors.
dissertation we have looked at the growth regulatory factors produced in
vitro by the tumor cells and have attempted to establish a testable
model of HSV transformation and tumor induction.
1
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Transformation by HSV is an exception to normal tumor virus action.
Tumor viruses are found among both DNA- and RNA-containing viruses
All RNA tumor viruses belong to the retrovirus group in which(7,8).
the viruses are characterized as containing an RNA-dependent DNA
polymerase which functions in producing a double-stranded (DS)
This DNA molecule is circularized andcomplement of the RNA genome.
inserted into a host cell chromosome as a necessary part of the
All of the transformingreproduction of these retroviruses.
retroviruses contain oncogenes (v-onc), which are believed to have
originated from cellular proto-oncogenes by inappropriate recombination
These oncogenes are required for the induction and maintenance(8,9).
of the transformed state.
All of the groups of DS DNA-containing viruses contain members with
demonstrated oncogenic potential (7,10). In the papovavirus group, in
which the DS DNA is circular, all of the members are oncogenic. In at
least one case, that of the simian virus SV-40 the entire viral genome
is integrated into a host cell chromosome as is evidenced by the fact
that the virus can be "rescued'’ from the transformed cells by fusing
In cells transformed by athem with permissive non-transformed cells.
number of other DS DNA-containing viruses, only a portion of the viral
genome is integrated as shown by hybridization techniques. These
integrated genomic fragments have been shown in some instances to
contain specific genes which are necessary for induction and maintenance
of the transformed state.
For the HSV no specific gene or gene product has been consistently
and in several reports (11-13) no stableassociated with transformation
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HSV genetic material has been demonstrated after continued passage of
This lack of stability has proven to be a difficult problemthe cells.
in the elucidation of the mechanism of HSV-induced transformation.
In spite of these observations HSV is still believed to induce
transformation by an alteration in the genetic make-up of the cell.
This alteration allows the transformed cell to escape the tightly
For normal cells, polypeptidecontrolled cell proliferation cycle.
growth factors acting in a carefully orchestrated fashion stimulate
Growth factors exert their control of celltheir proliferation (14-16).
proliferation by binding to specific receptors expressed on the cellular
The cells activated by these growth factors share amembrane (15) .
common phenotype with transformed cells and appear to activate the same
Because of these similarities, one of the moremetabolic pathways (16).
plausible explanations for oncogenic transformation is the deregulation
of the cell cycle by mimicking growth factors and/or their receptors.
This, in fact, has been demonstrated for RNA tumor viruses where several
oncogene products share homology with growth factor receptors, and one,
the simian sarcoma virus oncogene v-sis, shares homology with the gene
for the chain of platelet-derived growth factor (17). DNA tumor virus
oncogenes do not share homology with cellular genes but appear to act by
affecting the regulation of the cellular homologs of the oncogenes, the
This does not appear to be the case for HSVproto-oncogenes (10,18,19).
where no specific gene transcript is involved in this deregulation
In an attempt to determine possible routes of HSV(20,21).
deregulation, genetic alterations, we have looked at the growth factors
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produced by the transformed cell as a possible mechanism for this
transformation.
In the succeeding pages we will first review information pertinent to
the dissertation, specifically HSV tr-ansformation, growth factors and
spleen cell growth inhibitors, followed by two papers characterizing the
growth regulatory factors produced by the H238 tumor cell line, and
finally a discussion of a proposed model for the interactions of these
factors in tumor formation.
HSV Transformation
HSV became a tumor virus candidate through the epidemiological
studies of Rawls (22) and Nahmias (23) . They observed a statistically
significant association in women with cervical carcinoma with the
presence of serum antibodies to HSV, implicating the virus in the
Duff and Rapp (24,25) provided the firstetiology of a human tumor.
direct evidence for the transforming potential of HSV. A UV-irradiated
HSV was employed to transform in vitro cultured hamster fibroblasts. In
order to eliminate the reproductive capacity of the HSV, the virus was
UV-irradiated, damaging the viral DNA and blocking action of the DNA
The inactivated virus was capable of infecting the hosttranscriptase.
cells and contained essentially a full complement of genes including
This demonstration set in motion a searchpotential viral oncogenes.
for the molecular mechanism by which HSVs induced transformation.
Since that first report HSV has been used to transform a wide variety
Mouse (1,26,27), rat (20,28), and human lung and embryonicof cells.
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cells (29) have been transformed using HSVs that have been inactivated
(1,24,26,30),by a variety of means: UV-irradiation temperature
sensitive mutants (31,32), photodynamic inactivation (24,26,30), sheared
most recently, restriction enzyme-cut viral DNADNA fragments (33), and
fragments (20,31,34-38).
The search for viral-coded mRNA in transformed cells (39-42) was
successful but transcripts representing only 5 to 13% of the HSV genome
This observation pointed out the possibility thatwere detected.
incorporation of the entire viral genome was not necessary to transform
(43) demonstrated viral genomeFrenkel and associatescells.
incorporation using DNA:DNA hybridization. They detected the presence
of HSV DNA in the transformed cell after cloning the transformed cells
but observed that as in vitro passage history increased, and/or passage
through an animal host, the amount of viral DNA present in the cell
The transformed cell apparently only retained thosedecreased.
sequences necessary for maintaining the transformed state.
Several laboratories began to look for specific transforming
sequences using defined fragments of HSV DNA produced by restriction
With these fragmentsenzyme cleavage of the HSV genome (20,31,34-38).
region of the HSV-1 (20,35) and two regions of the HSV-2 genomesone
Significantly, neither(20,36,37) were found to induce transformation.
of the two HSV-2 transforming regions showed any sequence similarity to
The HSV-1 transforming region, mapping betweenthe HSV-1 region (20).
0.31 and 0.42 map units (MU), was found to code for a membrane
glycoprotein leading to speculation of its possible function in
transformation.
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Two HSV-2 transforming regions have been reported from laboratories
one mapping between 0.56 andemploying different selection criteria,
Galloway and0.63 MU (20) and the other between 0.48 and 0.58 MU (37).
McDougall (36) attempted to unify the data from several different
reports to determine if there really were two regions of the HSV-2
They cloned the restrictiongenome with transforming potential.
fragments into plasmids and amplified them for easier manipulation.
Their study indicated a single region of the HSV-2 genome, mapping
between 0.58 and 0.63 MU, that was capable of altering the morphological
phenotype of murine tissue culture cells and was tumorigenic in newborn
Subsequently, they found that this region did not encodeand nude mice.
a complete protein (21), making comparison to an oncogene difficult.
Further, they could find a copy number of only 0.1 copies per cell of
the HSV-transforming region (36).
Implied in the early work on HSV transformation was the idea that
transformation involved the stable incorporation of viral genetic
material and its expression in the transformed cell. With the report of
Galloway and McDougall (36) this became a questionable hypothesis.
First Skinner (11), then Galloway and McDougall (12), and later Cameron
and associates (13) proposed a "Hit and Run" hypothesis for the
Skinner, using a relativelymechanism of HSV transformation.
was unable to repeat the earlier work of Frenkel andinsensitive assay
associates demonstrating viral DNA in the transformed cells. He
proposed a model of transformation where debilitated HSV initiated the
transformation but was discarded by the newly transformed cell during
mitosis because it was not integrated into the cell's DNA.
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With this model in mind several laboratories began to look for
activation, by a "Hit and Run" HSV, of endogenous retrovirus (30,44-46),
(this virus family contains the RNA tumor viruses) the theory being that
these activated retroviruses were the etiological agents that induced
The search was successful;and maintained the transformed state.
retroviral activation was demonstrated in several rodent cell lines
transformed by debilitated HSV. But recently Duesberg (47) has argued
persuasively that only mutated retroviruses containing oncogenes are
able to transform, clouding the significance of the above observations.
Subsequent to Frenkel and associates' reporting (43) stable HSV
genetic material in the HSV-transformed cells other laboratories have
been able to reproduce these results with other HSV-transformed cell
Reyes and coworkers (20) demonstrated the stable incorporationlines.
of the HSV-2 restriction fragment, 0.58-0.63 MU, into the transformed
Galloway and McDougall (36), utilizing the same restrictioncells.
fragment, demonstrated similar results with low copy number per cell.
But after passage through an animal host the in vivo tumor cells had an
increased copy number of viral DNA per cell suggesting selection for
viral DNA-containing cells to maintain oncogenicity.
Currently Galloway and associates (21) have dissected the HSV-2
restriction fragment, 0.58-0.63 MU, and reported a 737 base-pair segment
that has insertion sequence-like structures. They propose an insertion
promotion mechanism for transformation similar to that reported with
This has yet to be demonstrated but couldsome other retroviruses.
No reports have yetaccount for deregulation of growth factors.
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appeared in the literature that develop the relationship between HSV-
induced transformation and specific growth factors.
The H238 Tumor System
The H238 tumor cell line in this study was originally derived from
cells transformed in vitro by infecting 238 cells, a BALB/c mouse
embryonic fibroblast cell line, with UV-inactivated HSV-2 (strain
The parental 238 cells are not able to produce tumors in 
vivo at inoculums of 1 x 10^
Savage) (1).
Debilitation of the HSV-2 wascells.
accomplished by eight minutes of UV-irradiation. Transformation of 238
cells was induced by infection with the debilitated virus at a
Putatively transformed H238multiplicity of infection equal to one.
cells were selected from foci after continued passages of infected cells
the basis of altered colony morphology. The selected cellson
demonstrated loss of both contact inhibition and an ability to grow in
The presence of HSV-2soft agar, characteristics of transformed cells.
proteins could be demonstrated in the original clones of transformed
cells by cytofluorometric analysis but attempts to recover infectious
After passage in our laboratory we havevirus have been unsuccessful.
not been able to find expression of the HSV-2 proteins previously
reported (unpublished observation by Dr. Kettering).
The oncogenic potential of the newly transformed H238 cell line was
evaluated and established by subcutaneous inoculation of the cells into'
the syngeneic BALB/c host. The tumors produced are invasive sarcomas,
not otherwise differentiated, in the soft tissue of host animals. They
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are well vascularized with enlarged lymph nodes in the proximal area,
and metastasis occurs, most frequently to the lungs (2).
Our previous work has detailed dietary modifications that alter host
BALB/c mouse response to H238 tumor challenge (2-5). We have compared
the effects of tumor challenge on mice fed various amounts and sources
We have observed differences inof carbohydrate, protein and lipids.
tumor incidence, tumor volume, relative spleen weight, spleen cell
differential counts, cell-mediated immunity, and decreasing lymphocyte
blastogenesis with increasing spleen weight and tumor volume (3,4). The
spleens of tumor bearing mice show an increase in compact myeloid
tissue, lymphoid nodule reactive centers, and red pulp volume (2).
Further, we have shown that the inhibition in lymphocyte blastogenesis
is mediated by cells of macrophage phenotype whose presence is required
for the inhibition to occur (5).
Growth Factors
Growth factors are technically defined as polypeptides that produce
their physiological effects by binding to specific receptors present on
Unlike classical hormones they arethe target cell's membrane (14-16).
produced and act locally after a short diffusion (14-16). The receptor-
growth factor interaction initiates a chain of cytoplasmic and nuclear
events that culminates in the initiation of DNA synthesis. The ongoing
discovery and elucidation of these events and their consequences remains
an important challenge of molecular biology.
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Originally, growth factors from other sources were isolated on the
basis of their ability to induce proliferation in tissue culture cells.
Currently, the observed effects of growth regulatory factors encompasses
a wider spectrum of activities, from proliferation and inhibition
effects to the induction of differentiated states. For example one
growth factor, transforming growth factor p (TGF-/?), first characterized
by its ability to support anchorage-independent growth in soft agar
cultures, is now believed to be a bifunctional regulator inducing
proliferation in some cell types while inhibiting other types (48,49).
While other growth factors, such as interleukin-1 (IL-1), first thought
have been found upon closer examination toto be tissue specific,
produce physiological effects in several cell types (50,51).
The demonstration of the bifunctional nature of TGF-/3 has renewed
interest in the study of factors that maintain cell homeostasis. The
study of these negative regulatory factors has a long history but they
have not received as much recent attention as growth factors. Chalones,
inhibitory factors were originally designated, have proven to beas
TGF-/3 and the interferonsdifficult to isolate and characterize (52).
(IFN) are the best studied examples of inhibitory factors that are
involved in maintaining the delicate balance between growth and
quiescence (53,54).
The identification of polypeptide growth regulators arose from the
observation that serum, an additive to tissue culture medium, contained
factors necessary for in vitro cell growth and multiplication. With
this intuitive knowledge, several laboratories (55-58) developed cell
proliferation assays and applied biochemical protein purification
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techniques to isolate and characterize specific growth factors. Leof
using a fibroblast proliferation model,(59),and associates
demonstrated that an orchestrated interaction of three growth factors
was necessary for quiescent cells to initiate and then complete the cell
They proposed a competence and progression model (59) forcycle.
fibroblasts that corresponded to classically described Gq/G-^ transition 
and late G-^/S progression, respectively (60) . 
platelet-derived growth factor (PDGF) induces a competent state while 
progression is regulated by epidermal growth factor (EGF) priming and
For the fibroblasts,
subsequent driving to completion by insulin-like growth factors (IGF).
The competence and progression hypothesis also holds true for other
proliferation models, for example the lymphocyte model where antigen and
IL-1 regulate competence and IL-2 controls progression (61,62). This
will be discussed in a succeeding paragraph.
Concurrently it was noted by others (63,64), that tumors cells
characteristically required less exogenous serum for in vitro growth.
Applying similar isolation methods it was discovered that transformed
cells produce endogenous growth factors that appear to affect their own
proliferation. These observations led Sporn and Todaro (65) to propose
autocrine and paracrine hypothesis by which the transformed tumoran
cell could maintain itself and gain an advantage over normal tissue. 
Autocrine stimulation is defined as the production of growth factors by
the tumor cells bearing receptors for the factor. Paracrine stimulation
involves the production of growth factors by the tumor cells that affect
the surrounding tissues causing them to interact with the tumor in a
beneficial way, producing factors necessary for tumor growth and the
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migration of tissues required by the growing tumor, one example being
angiogenesis.
Another intriguing development, that is still unfolding, was the
observation of a relationship between growth factors and oncogene
products (66,67) and that growth factors could regulate the expression
the normal cellular homologues of theof proto-oncogenes (68-71)
Two growth factor genes have been identified as transformingoncogenes.
genes: 1) the v-sis oncogene of simian sarcoma virus has extensive
homology to the /?-chain gene of PDGF (17), and 2) the int-2 gene, having
homology to the fibroblastic growth factor gene, has been reported to be
the transforming gene of Kaposi's sarcoma (72). The v-erb-B (73) and v-
fms (74) oncogenes appear to share homology with the genes of the EGF
and colony stimulating factor-1 (CSF-1) receptors, respectively.
Further, growth factors have been shown to regulate the expression of
c-myc (68,69) , and c-myb (71)nuclear proto-oncogenes c-fos (69,70)
c-fos and c-mycwhich in turn correlate to cell cycle progression, 
expression occur during Gq/G-^ transition and are induced by competence
c-myb expression
occurs during the late G-^/S phase of the cell cycle and has been linked 
to interleukin-2 activation of the lymphocyte model (78,79).
factors such as PDGF and interleukin-1 (IL-1) (75-77).
This has
provided the scientific community with a testable model for
and a plausible explanation for the relaxed control oftransformation
the cell cycle seen in transformed cells.
A short review of the biochemical and physiological characteristics
well-defined growth regulatory factors follows.of several
13
Proliferation factors are reviewed first, followed by descriptions of
inhibitory factors.
Growth Regulatory Factors
Platelet-derived growth factor (PDGF) is the major mitogen of serum
This heterodimer glycoprotein has a molecular mass of 30-32(80,81).
kilodaltons (kDa) that is made up of a 14-18 kDa a chain and a 16 kDa
First purified from human platelets, it has now been shown to bechain.
produced by placenta, endothelial cells, aortic smooth muscle, and
tumors of mesenchymal origin which synthesize a p-f3 chain homodimer.
Receptors have been demonstrated on a variety of mesenchymal cells,
The latter have about 400,000placenta trophoblasts, and fibroblasts.
The c-sis proto-oncogene codes for the p chainreceptors per cell.
while the v-sis oncogene is the transforming gene of simian sarcoma
Besides being a potent competence factor for fibroblasts,virus (17).
PDGF elicits a chemotactic response in fibroblasts and smooth muscle
(82) and is believed to be an important component of the wound healing
process (83).
Epidermal growth factor (EGF) is a 6 kDa single chain polypeptide
It is mitogenic for a variety of mesenchymal and epithelial cells(84).
and induces aspects of differentiation in certain cell types. It is an
important component of tooth eruption (85) . EGF effects are potentiated 
by insulin and EGF acts synergistically with PDGF in fibroblasts (59) . 
Expression of the EGF gene has been observed in a wide variety of
To the present time no tumor cells have been found thattissues.
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produce EGF, but several produce a similar molecule, TGF-a (see below),
that binds to the EGF receptor (86,87). TGF-a is believed to be an
The v-erb-B oncogene, the transforming gene ofembryonic form of EGF.
the avian erythroblastosis virus, is homologous to the EGF receptor gene
except that the EGF binding region is deleted in the oncogene product
EGF is reported to regulate its own receptor expression (88) .(73).
EGF binding causes an initial disappearance of the receptor from the
membrane, but binding increases the transcription of the receptor gene.
Insulin-like growth factors (IGF) are a family of 7 kDa peptides that
are insulin-like in amino acid sequence and act on a variety of
mesenchymal and epithelial cells (89) . IGF-1 somatomedin C, is an
important component of serum and plasma having mitogenic activity in a
large number of cell types and has been isolated from tumor cells. The
IGF-1 receptor gene is similar to the family of c-src proto-oncogene
tyrosine kinases with the f) chain of the receptor sharing sequence•rv>'
The mitogenic activity ofsimilarity with the c-ros proto-oncogene.
v
k
insulin itself has been shown to be mediated through the IGF-1 receptor
The role of IGF-2 in the proliferation process is more(90).
controversial with reports ranging from no activity (91) to action as a
mitogen (92) and/or the regulation of calcium influx (93) . IGF-2 has
been identified as the skeletal growth factor described by Baylinknow
The IGF-2 receptor has recently been cloned andand associates (94).
Besides binding IGF-2 itshown to be a bifunctional receptor (95,96).
also binds mannose-6-phosphate which is believed to be important in
intracellular lysosomal enzyme trafficking (97).
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Members of the interleukin (IL) family of growth factors are related
by their ability to stimulate the proliferation of lymphocytes and other
IL-1 is a 12-16 kDa single chain peptide that is ahematopoietic cells.
potent competence factor for lymphocytes (61,76). It is believed to be
integral component of antigen presentation to lymphocytes byan
IL-1 induces the production of other hematopoietic growthmacrophages.
factors, colony stimulating factors (see below), in fibroblasts (50) and
vascular endothelial cells (98), and to be an agent of inflammation (99)
IL-2, the major mitogen of the T-lymphocyte, is aand chemotaxis (100).
Lymphocytes must first be activated by15 kDa glycoprotein (62,101).
IL-1 and antigen before receptors for IL-2 appear on the plasma membrane
Antigenic challenge induces the production of IL-2 and the(102).
expression of IL-2 receptors on lymphocytes; this is an example of the
autocrine hypothesis working in normal tissues. IL-2 can also up-
regulate its receptor expression after an initial down-regulation of the
IL-2 receptor complex (69,102).
regulate the growth and(CSF)Colony-stimulating factors
differentiation of hematopoietic precursor cells (103,104). Several
glycoproteins have been described. They are: CSF-1, a 70 kDa homodimer,
CSF-2, a 15-28 kDa single chain protein, multi-CSF (IL-3), a 28 kDa
single chain polypeptide believed to be the stem cell growth factor,
granulocyte-CSF, a 24.5 kDa protein, and differentiation factor (D
factor), a 62 kDa protein apparently identical to another previously
The CSF-1 receptor is encoded by the c-fmsdescribed factor, MGI-2.
proto-oncogene (74).
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Fibroblastic growth factors (FGF), also referred to as heparin­
binding growth factors, are 14-18 kDa single chain proteins that have
They are mitogenic forslight sequence similarity to IL-1 (105,106).
culturedcells derived from embryonic mesoderm and neuroectoderm
fibroblasts, and vascular endothelial cells and induce angiogenesis in
Cells that are sensitive to the proliferative action of FGFvivo (107).
have about 20,000-40,000 receptors per cell. The FGF gene has been
implicated in the transformation of Kaposi's sarcoma cells (72), found
in patients suffering from acquired-immune deficiency syndrome (AIDS).
The int-2 transforming gene of Kaposi's sarcoma is homologous to the FGF
Recently FGF has been reported to act synergistically with TGF-/9gene.
in the induction of mesoderm formation during amphibian embryonic
development (108).
Transforming growth factors (TGF) derived their name from their
ability to stimulate the anchorage-independent growth of normal cells, a
characteristic usually associated with tumor cells (63,109). Several
types have been described but the most studied are TGF-a and TGF-/3.
TGF-a is a 5.6 kDa single chain protein that has sequence similarity
Its effectiveness on a molar basis equals that of EGF inwith EGF (87).
TGF-/? is a 25 kDa homodimer polypeptide that is capablemost systems.
It supports anchorage-independentof bifunctional regulation (48,49).
growth of suspension cultures while inhibiting the proliferation of
Inhibition by TGF-/?, in some cell lines ofmonolayer cultures.
epithelial origin, is achieved by the down-regulation of high affinity
TGF-/? has been reported to induce inEGF receptor expression (110).
vivo angiogenesis (107), chemotaxis of monocytes and macrophages (111) ,
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lymphocyte inhibition (99), differentiation of various tissues, and the
induction of PDGF synthesis in fibroblast cultures (112). It is
biosynthesized in an inactive form by most tissues and tumor cells and
Current -theory regarding itsmust be activated by acidification.
inability to inhibit tumor cells centers on the observation that tumor
cells have lost their ability to respond to the factor in a normal
Receptors, about 10,000-40,000 receptors per cell, forfashion (113).
TGF-/? have been found in all tissues tested.
Interferons (IFN) are potent inhibitors of cell proliferation that
will also stimulate the cell-mediated immune response (54). Three types
Originally IFN were described forhave been identified, a, (3, and 7.
their antiviral actions but now have been shown to inhibit proliferation
They inhibit Gq/G-^in a number of normal and transformed cells.
transition by interfering with the establishment of competence and the
IFN /3, a 20 kDa protein, isexpression of competence genes (114,115).
identical to a B-lymphocyte differentiation factor (116).
Several other negative growth regulatory factors have been described.
Among these are: fibroblast growth regulator, a 13 kDa single chain 
protein that inhibits fibroblast proliferation (117), inhibin, a 32 kDa
heterodimer related to TGF-/J that regulates follicle-stimulating hormone
secretion by the pituitary (118), and several tumor cell proteins (119- 
121) in the 13 kDa range that inhibit lymphocyte proliferation. Because
of the similarities in molecular mass, 12-13 kDa, of the single chain
proteins and dimer subunits, it has been suggested that these factors
may represent a family of proteins involved with the negative regulation
of cell growth (122).
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Tumor-Derived Inhibitory Factors
A large body of literature exists regarding the inhibitory effect of
tumor cells on the normal cell proliferation of the immune system.
Interest in this area, the direct effects of tumor cell products on the
positive effector cells of the immune system, has declined with the
discovery of an immune self-regulatory mechanism (T-suppressor cells)
Immune suppression is now believed to be mediated through(123-125).
Tumor cells could stimulate(126,127).this suppressor system
simultaneously the suppressor cells and the positive effector cells (T-
helper and/or -cytotoxic cells), thus inhibiting the positive response
Recently it has beenwithout the need of specific suppressor products.
demonstrated that positive effector cells (T-cytotoxic) could be
isolated from growing tumors and expanded in number in tissue culture
under the control of an immune cell growth factor interleukin-2 (IL-2)
When these cells were reintroduced intravenously, along with(128).
inactivation of the T-suppressor cells, the life span of the animals
and in some cases even eradication of the tumor occurred.increased,
Even if the suppressor system were an important component in the control
of the positive effectors, the presence of activated T-cytotoxic cells
in the locale of the tumor and their inability to inhibit tumor growth
again raises the question of what direct effect the tumor may exert over
the normal actions of the immune cells.
A variety of immunosuppressive agents isolated in vitro from either
fluids of tumor-bearing subjects or from the tumors themselves have been
19
These range from plasma and ascites fluids to solublizedreported .
tumor cell extracts.
The observed immunosuppression in cancer patients led researchers to
look for tumor-produced immunosuppressive agents in the serum and plasma
of human subjects (129-133) and human cell lines and animal models (119-
Several components of serum and/or plasma of tumor121,134-141).
bearing subjects were found to inhibit the immune response. a-Globulin
a-fetoprotein (131), low-density(130),(129), a-glycoprotein
lipoproteins (132), and prostaglandins (133) were shown to inhibit in
It was determined that none ofvitro spleen cell proliferation assays.
these components were tumor-specific. They were found also in normal
serum and/or plasma (142,143) and were probably not responsible for the
The isolation of immunosuppressiveobserved in vivo immunosuppression.
proteins produced by the suppressor lymphocytes (144-146) in response to
tumor burden cast further doubt on the validity of the interpretation of
the previously demonstrated immunosuppressive agents. Recently this has
come full circle with the demonstration of a difference in the nuclear
magnetic resonance profiles of the plasma low-density lipoproteins of
normal and tumor bearing subjects by Fossel and associates (147).
Direct inhibition of immunological assays by tumor cells and/or their
products has been demonstrated for a variety of tumors (119-121,134-
Inhibition of lymphoproliferation (119-121,134,138), IL-2141) .
production (119,121,134), antibody response (135), cytotoxic lymphocyte
development (119), and macrophage function (136) by tumor cell culture
Extracts and culture supernatants ofsupernatants are well documented.
melanoma tumor cells have been shown to inhibit lectin-induced spleen
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cell proliferation and IL-2 production (137,148). Mastocytoma products
inhibit mitogen-induced spleen cell proliferation and allogenic mixed
Cellular products of human tumors of thelymphocyte cultures (138,149).
colon (121,150) and esophagus (139), human leukemias (140), and human
tumor ascites fluid (141,151) inhibit in vitro immunological assays
The isolationdesigned to evaluate the competence of the immune system.
of normal cell products that inhibit similar in vitro immunological
assays (152-154) has demonstrated the need for careful evaluation of the
Inhibition of spleen cell proliferation by theisolated molecules.
artificial concentration of histones (152,153) and arginase (154), found
in the supernatants of normal cell cultures, has been reported.
Further, some inhibitors of immunological assays isolated from tumor
cell culture supernatants have been shown to be intact viruses (155) and
retroviral proteins (156,157).
Immunologists, in general, began to feel that these are all normal
cellular products that could inhibit in vitro spleen cell proliferative
They reasoned that the in vitro inhibition probably wouldassays (158) .
This idea coupled with the thennot be reflected in the in vivo system.
emerging knowledge of the immune system's self-regulation, with its
positive and negative effectors (123-125), led to a decreased interest
in tumor product inhibition of the immune response.
Several recent observations compel a partial rethinking of this
1) Rosenberg and associates (128) have isolated tumorposition.
infiltrating lymphocytes (TIL) and demonstrated their effectiveness in
adoptive immunotherapy; the TILs appear to be fully sensitized but
require in vitro clonal expansion with IL-2 before they have therapeutic
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2) Lau and coworkers (159) have demonstrated the successfulbenefit.
and superior therapeutic action of intralesionally-administereduse
biological response modifiers (BRM) in controlling tumor growth. 3)
Japanese investigators have observed a site-specific cell-mediated
immune response to inactivated lymphoma cells in animals bearing
progressive tumors of the same origin and have suggested that immature
cytotoxic T-lymphocytes (CTL) migrate to the tumor site and there
develop into mature CTLs (160).
The existence of the suppressor T-cells and their importance in the
control of the positive effector cells is not in question. The
necessity for the elimination of these T-suppressor cells before
successful adoptive immunotherapy can occur has been well-documented
Rosenberg and associates (128) found that administration(128,161,162).
of cyclophosphamide (Cy), a potent anti-T-suppressor cell agent, in
combination with TILs was necessary for therapeutic benefit to occur.
others before (161,162), only a marginalBut they demonstrated, as
effect on tumor burden or life span when Cy was given alone or in
What makes the TIL adoptive immunotherapycombination with IL-2.
procedure unique is the possible utilization of the animal's own immune
The fact that a smallcells and its application to human therapy.
number of sensitized effector cells could be demonstrated at the tumor
site and that these cells were not therapeutically effective within the
animal, even when suppressor activity was eliminated by Cy treatment,
points to the possible role of tumor products in the inhibition of the
Also, the finding that these cells were viablein vivo immune response.
and capable of in vitro clonal expansion, in the presence of growth
22
factors (IL-2) at therapeutic levels, may indicate a possible mode of
action for the tumor products.
Lau and coworkers (159) have demonstrated recently the superior
therapeutic effect of interlesional immunotherapy with immune modulators
The use of immunological modulators toC. parvum and A. sativum.
enhance the existing immune response owes its foundation to the
observation that some cancer patients have had miraculous recovery from
their tumors following a serious infectious disease. It is difficult to
assume that interlesional immunotherapy with C. parvum could eliminate
the local suppressor T-cell's activity as its mechanism of action for
the potentiation of CTLs. A more realistic mode of action would involve
the local recruitment of all the accessory cells necessary for a
positive immune response and a local increase in the IL-2 levels,
allowing the CTLs to escape suppression and perform their task.
Fuyama and his associates (160) have demonstrated the ability of
mice, bearing a progressive radiation-induced lymphoma (RL 1) on their
to induce a detectable CTL response to radiation-killed RL 1backs,
cells introduced into their peritoneal cavities. This is a somewhat
startling observation in light of the suppressor T-cell model. They
hypothesize the maturation of immature CTLs at the tumor site. Hardt
(161) have isolated an IL-2 inhibitor produced byand associates
suppressor T cells and theorized a mechanism for the control of the
nonspecific activity of IL-2 in a specific immune response. The
presence of high levels of IL-2 inhibitor in the animal serum may
possibly limit the activity of IL-2 to the close vicinity of the
These two theories are not mutually exclusiveproducer cell in vivo.
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and would fit well into the model of local inhibition of the immune
The immature CTLs could migrate to theresponse by tumor products.
tumor site but the tumor factors would inhibit their maturation and
clonal expansion.
Lymphocyte Proliferation Model
The discovery of T-cell growth factor IL-2 (101) has allowed
immunologists to dissect the response of the T-cell immune system to
Activation of the immature cytotoxic lymphocytesantigenic challenge.
(CTL) to their mature form requires two signals (62,101) corresponding
to the competence and progression states of the fibroblast model
Signal one, antigen binding to adescribed by Leof and associates (59).
clonally specific receptor, renders the cells receptive to the second,
The binding of IL-2 to itsor inductive, signal provided by IL-2.
nonclonally- distributed receptor (IL-2-R), expressed on sensitive T-
Cantrell andcells, triggers clonal proliferation, the immune response.
Smith (62) have utilized this two-step induction to demonstrate the
Thecompetent progressive model of the cell cycle with lymphocytes.
competent state is achieved when antigen (anti-T3-Ab), in the presence
combines with the antigen receptor (T3). IL-2-R appear on theof IL-1
cell membranes but the cells fail to move into the progressive state.
Addition of IL-2 to the cultures is required for movement into the
progressive state and lymphoproliferation to occur.
As with the fibroblast model proto-oncogene expression correlates
with competence and progression of the lymphocyte. Increased expression
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of the c-myc oncogene has been documented in lymphocytes when they are
stimulated with lectin mitogen (Con A) (68,163,164). Stern and Smith
(78) have recently demonstrated activation of specific proto-oncogenes
for the competent and progressive states of the stimulated lymphocytes.
Competence, antigenic interaction with lymphocytes, is associated with
an immediate increase in c-fos gene transcription, maximum at 30 minutes
(164), and a 10-fold increase in c-myc gene transcription at one hour
Progression, when IL-2 binds to the IL-2-R expressed on the(78).
competent cell, is associated with a four to six fold increase in c-myb
gene expression by five hours after IL-2 stimulation (78,79).
Statement of Research
In the papers that follow we will present evidence for four growth
Three of theseregulatory factors produced by the H238 tumor cell line.
factors are similar to previously described positive growth factors.
The fourth factor is a negative regulator of lymphocyte function.
Evidence will be presented to support the theory that these factors not
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The production of growth regulatory factors by H238, an HSV-2-
transformed mouse tumor cell line, was investigated. Serum-free
conditioned medium (H238-CM) contained both mitogenic and inhibitory
activity for DNA synthesis in specific cell types. H238-CM was
concentrated by ultrafiltration (1000 mol. mass cutoff) and fractionated
a heparin-sepharose affinity chromatography column. Mitogenicon
activity was separated into three peaks that eluted at: A) void volume,
B) 0.3-0.9 M NaCl, and C) 1.2-1.4 M NaCl. Inhibitory activity, peak D,
bound to heparin-sepharose and was eluted at 0.4-1.0 M NaCl, it was
distinct from the mitogenic activity of peak B. Peak A mitogenic
activity supported the anchorage-independent growth of EGF treated NRK-
c-49 cells resembling a transforming growth factor-/? (TGF-/3) - like
Peak B bound to lectin-coated sepharose beads and was sensitivefactor.
to trypsin, neuraminidase, and the reducing agent dithiothreitol (DTT).
These physical characteristics resemble platelet-derived growth factor
Peak C activity displaced basic(PDGF) suggesting a (PDGF)-like factor.
fibroblast growth factor (bFGF) in an RIA specific assay. Peak D was
inhibitory for lectin-stimulated splenocytes and allogenic MLR. It is
A model for thenot TGF-/3 but resembles interferon (IFN) in activity.
interaction of these factors with host will be discussed.
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The Isolation and Characterization of Growth Regulatory Factors Produced
by a Herpes Simplex Virus Type 2 Transformed Mouse Tumor Cell Line, H238
INTRODUCTION
Oncogenic transformation induced by herpes simplex virus (HSV) is an
No specific viral gene or geneexception among DNA tumor viruses.
product has been linked to the induction and maintenance of the
transformed state as is true for other DNA viruses (1) . Clearly the
restriction enzyme-generated DNA fragments of the HSV genome capable of
inducing transformation (2) do not encode a complete protein (3). This
has led to the proposal of a "hit and run" mechanism for HSV
transformation (4-6).
One restriction fragment, the Bgl II N, mapping between 0.58 and
0.63 map units of the HSV genome contains a 737 base pair region with
(3). This observation allowsinsertion sequence-like structure
comparison with nononcogene containing retroviruses which transform by
Isolation andinsertion activation of cellular genes (7).
characterization of growth regulatory factors produced by the HSV-
transformed cells would provide evidence for activated genes of the host
possible mechanism for induction and maintenance ofand a
transformation.
Autocrine stimulation of tumor cells by growth factors is believed to
be a significant means by which they escape the normal regulatory
Growth factors interact with cells throughmachinery of the cell (8) .
their specific receptors activating proto-oncogenes and driving cell
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Growth factors are not as a rule the products ofproliferation (9,10).
transforming genes, but two known exceptions are: the product of the v-
sis oncogene which has homology to the /?-chain of platelet-derived
growth factor -(11); and the product of the int-2 transforming gene of
Kaposi's sarcoma which has homology to fibroblastic growth factor (12).
This study was undertaken to characterize the growth regulatory
factors produced by an HSV-2 transformed cell line, H238. We report
four factors secreted into the tissue culture medium under serum free
Three of these factors are positive growth factors and theconditions.
The emphasis in thefourth is an inhibitor of cell proliferation.
present paper will be on the identification of the positive growth
A more detailed description of the inhibitory factor's actionfactors.
on splenocytes will appear separately.
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MATERIALS AND METHODS
The H238 cell line (13) received from Dr. A. L. Boyd is aCell Lines.
BALB/c embryonic fibroblast cell line that has been transformed in vitro 
by a UV-inactivated herpes simplex virus Type 2 (Savage strain), 
induction in the synergistic BALB/c host is 100% when 1 x 10^
Tumor
cells are
injected subcutaneously into the right thigh (13,14). Cells were
routinely maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO,
Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Irvine 
Scientific, Irvine, CA) 2 mM glutamine and 50 ug/ml gentamycin at 37°C
and 5% CO2-
To collect serum-free CM,
otwo-thirds to three-fourths confluent in 75 cm tissue culture
H238 cellH238 Conditioned Medium (CM) .
cultures,
flasks, were first washed three times with serum-free DMEM, then fresh
Cultures were incubated at 37°C for one toserum-free DMEM was added.
two hours at which time medium was again replaced with fresh serum-free
H238-CM was collectedDMEM supplemented with glutamine and gentamycin.
every 48 hours for one to two weeks depending on the culture.
Collection was terminated if the cell sheet sluffed off the culture
flask plastic surface; medium from cultures with floating cell sheets
CM was clarified by centrifugation, pooled and frozen atwas discarded.
-70°C until use. Concentration, approximately 10 fold, and dialysis
were performed using an Amicon ultrafiltration system. The original
ultrafiltration was done with a YM-2 membrane (1000 mol.wt. cutoff) and
dialyzed against phosphate buffered saline (PBS, 150 mM NaCl, 18.3 mM
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Na2HPO^, 1.7 mM NaH2POZf); subsequently they were concentrated with a YM- 
5 membrane (5000 mol.wt. cutoff) and dialyzed against 50 mM NaCl, 10 mM 
Final protein concentration was from 0.5-1.5 mg/ml asTris (pH 7.4).
determined by Bradford dye binding (15).
H238-CM in 50 mM NaCl (0.2-1 mg/ml; 10FPLC Affinity Chromatography.
ml) was applied to a FPLC Heparin-Sepharose CL-6B affinity column (1.5 x
The column was equilibrated with 1009 cm; Pharmacia, Piscataway, NJ).
mM NaCl, 10 mM Tris (pH 7.4) at a flow rate of 1 ml/min. Bound protein
was eluted with a 0.1 to 3.0 M NaCl gradient. Fractions comprising the
major growth-inducing activity were pooled.
*5[H]-Thymidine (TdR) Incorporation Assay.
H238-CM and the Heparin-Sepharose fractions of it were assayed by a two
"3hour incorporation of [ H]-TdR (ICN, Irvine, CA) into embryonic chick 
calvarial cells after an 18 hour incubation with putative growth factors
The mitogenic activities of
This assay has been adapted from the method of(effectors).
(16) and described in detail previously (17).Gospodarowicz et al.
Briefly, embryonic chick calvarial cells are enzymatically dissociated
from 15-day embryos with 1.5 mg/ml collagenase (Worthington Type 1) in 
Puck's calcium- and magnesium-free saline G.
passed through a nylon mesh and counted with a 
Cell concentration was adjusted to 1 x 10^ cells/ml in 
Cells (0.5 x 10^ cells/well in 0.5 ml final volume)




were plated in 48 well culture plates (Costar) and incubated for 24 
hours at 37°C before CM or heparin-sepharose fractions were added.
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Proliferation was assayed by [^H]-TdR pulse (2 /iCi/well, SA 50 Ci/mM), 
labeling which was terminated by washing cultures with phosphate- 
buffered saline and freezing the plates. Trichloroacetic acid (TCA)-
precipitable radioactivity was determined by swabbing the wells with
cotton-tipped applicators moistened with 12.5% TCA. Radioactivity was
quantitated by liquid scintillation counting of the washed swabs.
Assays consisted of 6 replicate culture wells/group. Treated groups
were compared to positive controls treated with 1% FCS and untreated
controls which received 50 jug/ml bovine serum albumin (BSA).
Statistical analysis of the difference between groups was done by
Student's T-test.
Transforming Growth Factor fl (TGF-yS) Assay. TGF-/9 activity was assayed
by the stimulation of NRK (Clone 49F) cell colony formation in soft agar 
culture as described by DeLarco and Todaro (18) . 
suspended (2 x 10^ cells/ml) in 0.3% agar in a medium consisting of
NRK cells were
equal volumes of DMEM and Ham's F12 supplemented with 10% FCS and
Effectors consisted of test sample with and withouteffectors.
epidermal growth factor (EGF) at 1 ng/ml. One ml of cell suspension was
added as a top-layer to 6-well culture plates (Falcon) over a 1.0 ml
bottom layer of 0.5% agar in the same medium without effectors, 
ten days incubation at 37°C colonies of greater than 20 cells ( >75 /zm
After
diameter) were counted in duplicate wells without fixation or staining
using an inverted microscope with 350X magnification and an ocular grid.
The colonies counted were similar in size and morphology to the large
colonies described by Roberts et al. (19).
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Fibroblastic Growth Factor (FGF) Radioimimine Assay (RIA). Bovine
pituitary basic FGF (bFGF) purified by Heparin-Sepharose chromatography
125D. Gospodarowicz) was radioiodinated ( I, Amersham,(gift of Dr.
Arlington Heights, IL) with lodogen (Pierce, Rockport, IL) . Antiserum
to bFGF (residues 1-24) was a rabbit polyclonal serum (gift of Dr. A.
Assay buffer consisted of 50 mM Na phosphate (pH 7.2), 0.1% BSABaird).
Reaction mixture (500 jul) consisted of 200 /il buffer,and 0.05% NaN^.
100 /il effectors (standards or competitors) , 100 /il antiserum (final 
dilution 1:2 x 10^) and 100 /il ^^I-labeled bFGF (25,000 cpm total).
Mixtures were incubated at 4°C for 24 hours. Separation of the bound
and free labeled bFGF was accomplished by precipitation of bound
complexes when 100 /il of a goat anti-rabbit gamma-globulin mixture and
200 ul of a non-immune rabbit serum utilized as a carrier (2% in buffer)
Reaction mixture was again 
incubated at 4°C for 24 hours and then centrifuged at 500 x g for 20
were added to the reaction mixture.
Supernatants were decanted and the pellet counted in a gammaminutes.
Typically, this RIA could measure from 0.6 to 20 ng/ml bFGFcounter.
with 50% displacement occurring at approximately 3 ng/ml and 90%
Interassay variation was 10% withdisplacement with about 20 ng/ml.
nonspecific binding of 10% of the total counts precipitated. Total
specific counts bound in the absence of competitor was 4000 cpm's. The




Serum-free conditioned medium (CM)Detection of Growth Factor Activity.
from H238 tissue cultures was concentrated approximately ten fold with a
1000 mol. wt. cutoff.Amicon ultrafiltration system utilizing a
Mitogenic activity was detected in the concentrated CM when tested at
3
protein concentrations of 3 and 10 /xg/ml in a [ H]-TdR incorporation
The binding of the mitogenic activity to heparin-assay (Table 1) .
sepharose was determined utilizing a Pharmacia FPLC chromatography
A concentration gradient of 0.1-3.0 M NaCl was used forsystem.
elution, and 2 ml fractions were collected.
3in the [ H]-TdR incorporation assay.
These fractions were tested
Mitogenic activity was found to be
and C (Fig. 1) . Because ofseparated into 3 peaks, designated A, B
this laboratory's interest in inhibitors of lymphocyte proliferation
(20) the fractions were tested in a lectin-induced lymphoproliferation
An inhibitory activity was detected eluting with the middle peakassay.
B of the mitogenic activity and designated peak D (Fig. 2).
Because H238 cells can grow as anchorage-Characterization of Peak A.
cultures in soft agar (13,14) the CM was tested forindependent
CM, with and without acidtransforming growth factor activity.
treatment, was able to support anchorage-independent growth but only in
the presence of EGF indicative of TGF-/3 like activity (Table 2). Peak A
which did not bind to heparin-sepharose was subsequently tested for TGF
activity and similar results were found (Table 2).
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Peak B eluted from the heparin-sepharoseCharacterization of Peak B.
It was found to be sensitive to trypsin,between 0.3-0.8 M NaCl.
It bound to lectin-coated sepharoseneuraminadase, and DTT (Table 3).
beads and was stable at mild acidic conditions (pH 6.4) (170 vs 166 % of
control).
Peak C eluted from the heparin-sepharoseCharacterization of Peak C.
When dialyzed against 0.05 Mbetween 1.1-1.4 M NaCl of the gradient.
acetic acid (pH 6.4) all mitogenic activity was lost. Because FGF is
the only growth factor known to bind this tightly to heparin-sepharose,
the CM and heparin-sepharose fractions were tested by an RIA assay
CM displaced labeled-FGF in a dose dependent manner. FGF-(Table 4).
like activity from tumor CM was found to be approximately 7 ng/mg of
total CM protein which was consistent for several separate collections
of CM.
Coeluting with peak B (0.4-0.9 M NaCl) wasCharacterization of Peak D.
a growth inhibitor of lymphocyte proliferation. This activity was found
to inhibit a variety of in vitro immunological function assays (Table
5).
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Table 1 Production of mitogenic activity by 
H238 tumor cell line
1 x 10 cells were plated in 0.5 ml of serum free medium on 48 well 
tissue culture plates. After 24 hours effectors were added. 24 hours 
later incorporation of [3H]-TdR into the acid-precipitable fraction was 





191.8 ± 41.7 100.0Control
1784.3 ± 304.2 930.2 ± 1581% FCS
288.7 ± 23a553.8 ± 44.2H238 CM 3 /zg/ml
379.4 ± 80a727.8 ± 153.710 ng/ml
a P < 0.001
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Table 2 TGF activity 
NRK colony formation in soft agar
2000 NRK-C-49F cells per plate in 0.3% agar medium containing 10% FCS. 
Effectors were added at the concentrations indicated in the presence or 
absence of 1 ng/ml EGF. Colonies > 75 jum were scored. Values represent 






20020 Mg/ml 0H238 CM
0 20620 /ig/mlH238 CM 
(acid treated) 
Hep-Seph Fraction 9 
(0.1 ml in 2 ml)
4650
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Table 3 Stability of peak B growth factor to treatment 
with reducing agents, enzymes, and lectins bound to beads
Peak B effector was treated with reducing agent and enzyme for 180 
minutes at which time medium containing 10% FCS was added. 
Incorporation of [3H]-TdR into acid-precipitable fraction was assayed. 
Values represent the mean ± SE of six wells
■3[ H]-TdR incorporation (% of control)
Buffer
Control Peak BTreatment
100 226 ± 36None
123 ± 21 143 ± 11DTT
119 ± 18 117 ± 22Trypsin
128 ± 18106 ± 20Neuraminadase
(unbound)
166 ± 14130 ± 21Lentil lectin
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Table 4 RIA for FGF activity
100 pil of CM or heparin-sepharose fraction 21 were tested in a 
competitive binding assay with 125I-labeled bFGF against a rabbit 
polyclonal bFGF antiserum. Separation of bound and free labeled bFGF 
was accomplished by precipation with a goat anti-rabbit gamma-globulin. 














Table 5 Peak D growth inhibitory activity 
against spleen cells
For lymphoproliferation 2 x 10^ spleen cells in 0.2 ml of medium were 
induced with 2.5 pg/ml of Con A. Two days later the incorporation of 
[3H]-TdR was assayed after 
lymphocyte reaction 3 x 105
treated stimulating cells were plated in 0.2 ml of medium, 
later the incorporation of [3H]-TdR was assayed after a 12 hour pulse. 
Values represent the mean ± SE of triplicate wells.
a 5 hour pulse. For allogenic mixed 







107424 ± 11747Con A
32488 ± 11607a 69.8aCon A + H238 CM
II. Mixed lymphocyte reaction
40434 ± 8203Control
2042 ± 106b 94.9bH238 CM 220 pg/ml
7631 ± 1812a 81.la110 pg/ml
a P < 0.0001 

















0 5 10 15 20 25 30
Fraction Number
Serum-free H238-CM (10 mgFig. 1. Affinity chromatography of H238-CM. 
total protein) concentrated 20 fold by ultrafiltration was passed 
through an FPLC column of heparin-sepharose equilibrated with 10 mM
TwoColumn gradient was from 0.1-3.0 M NaCl.
Mitogenic activity was 
assayed by culturing chicken calvarial cells (2 x 104 in 0.5 ml) in 
Dulbecco' s medium containing 0.25 /xl of a 1:20 dilution of each fraction 
for the last 24 hours of the assay.
incorporation of [3H]-TdR into the acid-precipitable fraction, 
represent the mean % of control of six experiments.
100 mM NaCl.Tris,
milliliter fractions were collected at 1 ml/min.













0 5 10 15 20 25 30
Fraction Number
Serum-free H238-CM (10 mg 
was passed
Affinity chromatography of H238-CM.Fig. 2
total protein) concentrated 20 fold by ultrafiltration 
through an FPLC column of heparin-sepharose equilibrated with 10 mM
from 0.1-3.0 M NaCl. TwoColumn gradient waslOOmM NaCl.Tris,
milliliter fractions were collected at 1 ml/min. Spleen cell inhibitory 
activity was assayed by culturing splenocytes (2 x 10 in 0.2 ml) for 40 
hours with Con A (2.5 mg/ml) in RPMI 1640 medium containing 0.1 ml of a 
1:10 dilution of each fraction. Proliferation was determined by [ H]- 




The determination of a mechanism for transformation by herpes simplex
In an attempt to developvirus Type 2 has been difficult to elucidate.
a relationship between HSV-2 transformation and the current hypothesis
regarding the loss of growth control in tumors, the autocrine hypothesis
have looked at factors produced by an HSV-2-transformed tumor(8), we
In this study we have demonstrated four biologically-H238.cell line,
active growth regulatory factors that are produced and secreted into the
spent tissue culture medium of H238 cells. Three of these factors
possess activities that resemble classically described positive growth
The fourth is a negative growth regulator offactors for fibroblasts.
an as yet undetermined lineage.
The first growth factor does not bind to heparin-sepharose and
possesses transforming growth factor /?-like activity. It supports the
anchorage-independent growth of EGF-treated NRK (clone 49) cells in soft
agar.
The second mitogenic activity resembles a platelet-derived growth
It binds to heparin-sepharose elutingfactor (PDGF)-like protein (21).
It is sensitive to trypsin, neurominadase, andbetween 0.3-0.9 M NaCl.
the reducing agent DTT.
The third positive factor resembles a basic fibroblastic growth
It binds tightly to heparin-sepharosefactor (bFGF)-like activity (22).
(eluting from 1.1-1.4 M NaCl), is sensitive to mild acid treatment (pH
6.4) and displaces bFGF in an RIA.
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The fourth factor is a negative regulator that inhibits lectin-
It binds to heparin-sepharose, andstimulated lymphocyte proliferation.
elutes from it in the 0.3-0.9 M NaCl gradient region.
The production of TGF-^ and PDGF-like activities from a fibroblastic
tumor cell line is not an unexpected finding and probably not a unique
Production of PDGF like activity hasevent for HSV-2 transformation.
been reported in a wide variety of transformed and tumor cells (23). In
Leof and associates have demonstratedanother fibroblast line, ARK-2B
the induction of a PDGF activity and the transcription of mRNA
This may represent a self-homologous to c-sis by TGF-/3 (24) .
perpetuating deregulated loop of transformed fibroblasts where TGF-/3
induces PDGF which in turn induces TGF-/3 as part of its mitogenic
activity.
The demonstration of a negative growth regulator with inhibitory
activity for normal fibroblasts and lymphocytes may serve a dual purpose
First, the escape of thein the overall mechanism of tumor progression.
transformed cell from negative regulation would upset the homeostatic
Quite possibly thebalance observed in normal cells (25).
ineffectiveness of the negative regulation would allow for the
uncontrolled synthesis of the positive regulators seen in this HSV-2
Loss of the negative regulation of either TGF-/?transformed cell line.
and/or PDGF could account for the apparent deregulation observed.
Second, the inhibition of lymphocyte proliferation by a tumor cell
product would interfere with the hosts ability to mount an effective
It would allow for the infiltration into theimmune response.
developing tumor of competent immune cells possessing clonally-specific
44
receptors for the transformed cell but would inhibit the clonal
Rosenberg andexpansion typical of a successful immune response.
coworkers (26) have demonstrated tumor infiltrating lymphocytes that are
capable of successfully combatting a tumor upon in vitro expansion.
The demonstration of a factor that resembles a bFGF like activity is
It has been reported for other tumor cell linessomewhat controversial.
but when the gene for bFGF was cloned it was found not to possess a
signal peptide and therefore was believed to be cell-associated (27) . A
determination of any possible causal relationship of bFGF secretion and
herpes virus -induced transformation needs to be followed up in light of
In particular, this is true withthe transforming potential of FGF.
Kaposi's sarcoma where the int-2 gene has been implicated as the
transforming gene of the cells (12) and in light of the isolation of a
novel herpes virus found in several individuals suffering the
lymphoproliferative disorders seen in AIDS-related complex disease (28).
Further studies with other herpes virus-transformed cells to
determine causal relationships to deregulated growth regulatory factor
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Previous reports have indicated that mice bearing tumors from the H238
3Lymphoproliferation, [ H]-cell line have an impaired immune response.
thymidine (TdR) incorporation, is inhibited by serum-free conditioned
H238-CM was concentrated bymedium (H238-CM) from H238 cultures.
ultrafiltration (1000 mol. mass cutoff) and fractionated on a heparin-
A trypsin-sensitive growthsepharose affinity chromatography column.
inhibitor (H238-GI) was eluted at 0.4-1.0 M NaCl. H238-GI inhibited a
variety of splenocyte function assays: lectin-induced splenocyte
proliferation, allogenic mixed lymphocyte reaction, and production of 
IL-2 by lectin-stimulated splenocytes.
0.48 /ig/ml) [^Hj-TdR incorporation was inhibited (29-40 %, p < 0.004) by 
H238-GI, but [H]-uridine and [H]-leucine incorporation was unchanged. 
Pretreatment of spleen cells with lectin + H238-GI, followed by removal
In a dose-response study (0.12-
of the factor, had no lasting effect on the proliferation assay, but
when H238-GI was added back at 19 hours posttreatment, the cell
proliferation was again inhibited (32.6 %, p < 0.006). This indicated a
need for the continued presence of H238-GI for inhibition to occur.
Treatment of IL-2 dependent CTLL-1 cells with H238-GI showed a marginal
inhibition (14.3 % at 250 units of IL-2. p < 0.003), but when cells were
49
denied IL-2 for 24 hours, then given IL-2 in the presence of H238-GI
inhibition was increased, indicating a possible block in Gq/G-^ 
transition. To determine a possible site of H238-GI action within the
H238-GIcell cycle the c-myc proto-oncogene expression was examined.
inhibited c-myc transcription by 30 % at 3 hours post-lectin addition,
indicating possible arrest of the splenocyte proliferation cycle in Gq
by H238-GI.
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Lymphocyte proliferation in response to antigenic challenge is the
cornerstone of the immune system's ability to combat invasion by foreign
Factors which would interfere with this clonal expansionagents (1,2) .
would seriously impair the animal's ability to fight off infection and
A variety of factors isolated from the serum of tumor-tumor growth.
bearing animals (3-7), ascities fluid (8,9) and the tumor itself (10-
18) have been demonstrated to inhibit immune function assays. These
assays usually are in vitro proliferation assays, specific examples
being the mixed lymphocyte reaction and lectin-mitogen stimulation, and
indicate factors that inhibit the clonal expansion of the lymphocyte.
Lymphocyte proliferation is a two stage event (19,20), similar in
concept to the competence-progression model for fibroblasts proposed by
The unique aspect of this model is thePledger and associates (21) .
tight control of each stage by protein growth factors. In the
lymphocyte model, competence is established by the interaction of cells
with antigen and IL-1 (22) which induces competence factor genes (23-
IL-2 production (22,27,28) and IL-2 receptor expression in the26),
Progression is solely under the control of IL-2lymphocyte (29,30).
acting through its receptor to drive the cell through its cycle (29) .
Specific proto-oncogene expression is associated with both states. The
c-myc gene is a competence factor gene, expressed upon mitogen challenge
51
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The c-myb gene is expressed during progressionof lymphocytes (23-26).
(31,32).
We have been studying the immune response of mice to a DNA virus-
We have demonstrated a decline ininduced syngeneic tumor (33-35).
immune function with tumor growth mediated by a suppressor macrophage
In this paper we look at a factor produced by the tumor which(36).
inhibits a variety of immune function assays via inhibition of cell
By looking at proto-oncogene induction after lectin-proliferation.
mitogen stimulation we provide evidence that the factor inhibits the
establishment of a competent state thus allowing mature cells to




Animals and Cell Lines
BALB/c and C57B1/6 mice were purchased from The Jackson Laboratory-
Mice used in these experiments were immunocompetent,(Bar Harbor, Me).
from 10 to 20 weeks of age.
The H238 cell line (37) received from Dr. A. L. Boyd is a BALB/c
embryonic fibroblast cell line that has been transformed in vitro by a 
UV-inactivated herpes simplex virus Type 2 (Savage strain), 
induction in the synergistic BALB/c host is 100% when 1 x 10^
Tumor
cells are
injected subcutaneously into the right thigh (33). Cells were routinely
maintained in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand
Island, NY) supplemented with 10% fetal calf serum (FCS; Irvine
CA) 2 mM glutamine and 50 ^g/ml gentamycin at 37°CScientific, Irvine
and 5% CO2.
CTLL-1, an interleukin-2 dependent cell line (38), received from Dr.
D. Lyle, was maintained in RPMI-1640 medium (GIBCO Grand Island, NY)
supplemented with 10% FCS, glutamine, gentamycin, and 25% T-cell growth
factor-conditioned medium.
H238 Conditioned Medium (CM)
To collect serum-free CM, H238 cell cultures
ofourths confluent in 75 cm
two-thirds to three-
tissue culture flasks, were first washed
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three times with serum-free DMEM, then fresh serum-free DMEM was added.
incubated at 37°C for one to two hours at which timeCultures were
medium was again replaced with fresh serum-free DMEM supplemented with
H238-CM was collected every 48 hours for oneglutamine and gentamycin.
Collection was terminated if theto two weeks depending on the culture.
cell sheet sluffed off the culture flask plastic surface; medium from
CM was clarified bycultures with floating cell sheets was discarded, 
centrifugation, pooled and frozen at -70°C until use. Concentration,
and dialysis were performed using an Amiconapproximately 10 fold,
The original ultrafiltration was done with aultrafiltration system.
YM-2 membrane (1000 mol.wt. cutoff) and dialyzed against phosphate-
18.3 mM Na2HP04, 1.7 mM NaH2P04) ,buffered saline (PBS, 150 mM NaCl
subsequently they were concentrated with a YM-5 membrane (5000 mol.wt.
cutoff) and dialyzed against 50 mM NaCl, 10 mM Tris (pH 7.4). Final
protein concentration was from 0.5-1.5 mg/ml as determined by Bradford
dye binding (39).
FPLC Affinity Chromatography
H238-CM in 50 mM NaCl (0.4-1 mg/ml; 10 ml) was applied to a FPLC
Heparin-Sepharose CL-6B affinity column (1.5 x 9 cm; Pharmacia,
The column was equilibrated with 100 mM NaCl, 10 mMPiscataway, NJ).
Bound protein was eluted withTris (pH 7.4) at a flow rate of 1 ml/min.




The mitogenic activity of Concavalin A (Con A) and FCS were assayed 
by a five hour incorporation of [^H]- thymidine (TdR; ICN, Irvine, CA; SA 
50 Ci/mM; 1 /xCi/well) into spleen blast cells after a 35 hour
This assay has been described in detail previously (36) .incubation.
Briefly, spleens from normal BALB/c mice were mechanically disrupted,
washed in ACK lysing buffer (155 mM NH^Cl; 10 mM KHCO^; 0.1 mM Na2EDTA; 
pH 7.4) and the cells suspended in RPMI-1640 with 10% heat inactivated 
FCS (56°C 30 Min.), 2 mM glutamine, 25 /ig/ml gentamycin and 5 /iM 2-
Cells were counted with a hemacytometer and 
cell density was adjusted to yield a final concentration of 1 x 10^ 
cells/ml for each test.
mercaptoethanol (2-ME).
Cells were plated at 2 x 10^ cells/well (0.2 ml
[3H]-TdRculture plates (Falcon).in 96-wellfinal volume)
incorporation assay consisted of two sets of triplicate wells per test,
three received Con A (2.5 ^g/ral) and three received medium alone.
Treated groups were compared to maximal stimulation of splenocytes by 
Inhibitory activity was monitored by a decrease in Con A 
RNA and protein synthesis were determined by a five hour 
pulse of blastogenic spleen cell with [3H]-Uridine (SA 50 Ci/mM; 1 
/iCi/well) and [3H]-Leucine (SA 50 Ci/mM;
Con A or FCS.
mitogenesis.
1 /xCi/well) respectively.
Cells were harvested using an automated cell harvester (Brandel,




Spleen cells at a final concentration of 1 x 10^ cells/ml, in RPMI-
glutamine, gentamycin and 2-ME were induced to 
produce IL-2 by incubation with Con A (2.5 /ig/ml) for 38-40 hours.
1640 with 10% PCS
Each
test group consisted of 12 wells of a 96-well plate. IL-2-conditioned
medium from each test group was collected, centrifuged, pooled and 
stored at -70°C until assayed.
IL-2 Assay
This assay has been described in detail previously (40) . 
triplicate wells/test of 1 x 10^" CTLL-1 cells/well in a 96-well culture 
plate were incubated for 18 hours with serial two-fold dilutions of IL- 
2-conditioned media from each group.
hour pulse of [ H]-TdR (1 /xCi/well) at the end of incubation.
Briefly,
Activity was measured by a four-
Assays
harvested with a cell harvester and quantitated by liquidwere
Units of IL-2 were determined by probitscintillation counting.
The standard was 1 U/ml ofanalysis at 50% of the IL-2 standard.
recombinant IL-2 (Genzyme, Boston, MA).
Mixed Lymphocyte Reaction (MLR)
An allogenic splenocyte response was adapted from the method of
Stimulation of MLR was assayed by a 20 hourErickson et al. (^1).
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incorporation of [ H]-TdR (1 /iCi/Well) into blastogenic spleen cells. 
Briefly, responder BALB/c spleen cells were incubated with stimulator
Cells were plated into 96-well 
culture plates at a concentration of 3 x 10^ cells/well for each cell
C57B1/6 spleen cells for 5 days at 37°C.
Stimulator cells were prepared by 
incubation of 1 x 10^ cells/ml with 50 pg/ml mitomycin C for 30 min at 
37°C and washed thoroughly with RPMI-1640. 
cells alone and stimulator cells alone.
(0.2 ml final volume).type
Controls included responder
All assays were plated in
triplicate. Assays were harvested with a cell harvester and quantitated
by liquid scintillation counting.
RNA Isolation and Hybridization
Total cytoplasmic RNA was isolated by lysing spleenRNA Isolation:
cells with 0.5% (v/v) Nonidet P-40 (NP-40) in the presence of lOmM
vanadyl ribonucleoside complexes (BRL, Gaithersburg, MD). Lysed cells
were centrifuged to remove nuclei and organelles and extracted with
Following extraction the RNA was precipitated withphenol chloroform.
ice-cold ethanol and 0.15M sodium acetate. Precipitated RNA was
resuspended in 10 mM Tris (pH 7.4), 1 mM Na2EDTA, and 0.1% (wt/v) sodium 
dodecyl sulfate (SDS).
Purified RNA was prepared for analysis byDot Blot preparation:
application to nitrocellulose (NC) filters (Schleicher & Schuell, Keene,
NH) by a "Dot Blot" method proscribed by the manufacturer. Briefly, RNA
in 6X SSC buffer (IX is 150 mM NaCl, 15 mM sodium citrate) and 20% (v/v)
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formaldehyde was denatured by heating at 60°C for 15 min. Serial two­
fold dilutions (5, 2.5, 1.25 /ig total RNA) in ice-cold 20X SSC buffer
were made and then applied to NC filters using a "Minifold" Dot Blot
filtration manifold (Schleicher & Schuell, Keene, NH). Filters were air
dried and then baked under vacuum for two hours at 80°C.
Hybridization: NC filters were prehybridized in sealed plastic bags
for four hours at 42°C in a reaction buffer of 50% formamide, 5X SSPE
(IX SSPE is 150 mM NaCl, 10 mM Na^PO^^O and 1 mM Na2EDTA) , 5X
( SOX is 1% Ficoll 400, 1% BSA, 1%Denhardt's solution
Polyvinylpyrrolidone 360,000 mol.wt.), 0.5% (v/v) SDS and 100 /ig/ml
Hybridization was carried out in the same buffersalmon sperm DNA.
containing additions of 10% (wt/v) dextran sulfate (500,000 mol.wt.) and 
2 x 10^ cpm/ml [ ^P] - labeled CDNA probe. The cDNA probe was a 1800 base
pair Clal-Eco R1 restriction fragment of the human c-myc third exon
(Oncor, Gaithersburg, MD) and labelled with [32P]-dCTP (3000 Ci/mM; ICN,
8 Labeling wasIrvine, CA) to a specific activity of 1 x 10 cpm//jg DNA.
performed by the random priming method of Feinberg and Vogelstein
(Anal.Biochem 137:266 '84) utilizing an Oligolabelling Kit (Pharmacia,
Hybridization was carried out at 42°C for 48 hours.Piscataway, NJ).
At the end of hybridization NC filters were washed two times in 2X SSC
and 0.1% SDS at room tempature for 30 min. Final wash was 0.IX SSC and
0.1% SDS at 50°C for 30 min. Filters were exposed to Kodak XAR-OMAT 




The inhibition of the lectin-induced stimulation of splenocytes by
the conditioned medium of an HSV-2-transformed tumor cell line, H238
has been previously reported from this laboratory (42) . To aid in a
further study of this activity, serum-free conditioned medium (CM) was
The H238-CM was concentratedcollected from cultures of the H238 cells.
approximately 10-15 fold by ultrafiltration, using a 1000 mol. wt. cut
The concentrated H238-CMoff membrane, and dialyzed against PBS.
possessed a trypsin-sensitive factor that showed an increased inhibitory
activity when assayed in the lectin mitogen stimulation assay using PHA
and Con A (Table 1).
To determine whether the inhibitory factor was acting on the
splenocytes or just inhibiting their lectin-induced stimulation, the
growth inhibitory factor (H238-GI) was tested in an allogenic mixed
The inhibition of the MLR by the H238-GI waslymphocyte response (MLR).
Further, the H238-GI's effect on IL-2 productionpronounced (Table 2).
The spleen cells treated with H238-GIof the splenocytes was examined.
were markedly inhibited in their IL-2 response to lectin-stimulation
(Table 3).
While the growth factor activity produced by the H238 cells during
these experiments was being examined, it was observed that the
An aliquot containinginhibitory activity bound to heparin-sepharose.
10 mg total H238-CM protein was applied to an FPLC heparin-sepharose
affinity chromatography column. The fractions were assayed for
inhibitory activity and H238-GI was found to bind to the column and
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eluted between 0.4-1.0 M NaCl in the gradient (Fig. 1). The H238-GI
inhibited both lectin- and serum-induced proliferation of the spleen
Affinity chromatography-purified H238-GI was tested to determinecells.
its effects on the lectin-induced proliferation and IL-2 production. A
similar activity to that observed with the unfractionated CM was found
(Tables 1 & 3).
The inhibition of lectin-induced proliferation can occur at several
points in the macromolecular apparatus of the proliferating cell. To
determine a possible site of inhibitory action, the H238-GI factor was
3tested in a dose-response assay by pulsing the cells with either [ H]- 
TdR, [^H]-uridine, or [^H]-leucine (Fig. 2, Table 4). H238-GI
specifically inhibited DNA synthesis in a dose dependent manner while
not affecting the other macromolecular processes.
In order to determine if the H238-GI could affect proliferation by a
short interaction with splenocytes, lectin-exposed cells were pretreated
with H238-GI for 3 hours, then H238-GI was removed (Fig.3).
Removal of H238-GI restored [^H]-TdR
Control
cultures received no H238-GI.
incorporation to the levels of untreated spleen cells. When the H238-GI
was added back to the cultures at 19 hours post pretreatment, inhibition
This indicated that the inhibitory activity waswas observed.
reversible and its continued presence was required to cause its
antiproliferative effect.
It was of interest to determine a mechanism of action for the H238-
Several tumor-derived antiproliferative factors have been reportedGI.
to have immunosuppressive activities (10-18). It is probable the H238-
GI is a normal cell product involved in the homeostatic balance of cell
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proliferation that has lost its normal inhibitory activity on the tumor
The lymphocyte proliferation model requires two stepscell (Table 5).
for proliferation: 1) the Gq/G-^ transition induced by antigen and 
factors such as IL-1, and 2) the G-^-S phase under the regulation of IL-2 
First, a test of the ability of H238-GI to inhibit the IL-2-(29).
IL-2 dependent cell line CTLL-1 wasinduced proliferation of the
A slight inhibition of the IL-2 response was observed (10747performed.
This slight inhibition was not at the± 1192 vs 9211 ± 801 P<0.003) .
same levels as those observed in the lectin-induced cells. There was
concern that the inhibition was due to the small number of CTLL-1 cells
that were cycling through the early G^ phase during the 18 hour assay. 
To test this possibility IL-2 was removed from the CTLL-1 cells for 18
added with and without H238-GI.hours before fresh IL-2 was The
response of the CTLL-1 cells was followed for 24 and 48 hours.
Inhibition was more pronounced and its duration was throughout the
entire experiment (Fig. 4) indicating a possible action during the G^ 
phase.
The c-myc proto-oncogene is an early response gene in lectin-
stimulated lymphocytes (23-26) and is indicative of Gq/G-^ transition. 
It has also been implicated in the activation of DNA polymerase. In a
test to determine the possible relationship between H238-GI inhibition
and c-myc induction, cytoplasmic RNA was isolated in a lectin-induced
kinetic study with and without H238-GI. 
inhibited 30% at 3 hours (Fig. 5) corresponding to the level of
3
inhibition of [ H]-TdR incorporation observed in the proliferation assay
c-myc gene expression was
for this concentration of protein (Table 5).
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TABLE I
Inhibition of lectin-induced splenocyte proliferation
by H238-GI
[^H]-TdR incorporation




59732 (68)c 5177 (94) 10514 (88)H238 CM 288 mg/ml
20098 (77) 62405 (28)144 mg/ml 68309 (63)







a CM was treated with trypsin for 3 hours before 
addition of media and 10% FCS. 
b Values represent mean dpms of triplicate wells 
c % inhibited (control dpm - test dpm)/control dpm
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TABLE II
Effect of H238-GI on allogenic mixed lymphocyte cultures3
[^H]-TdR incorporation
Expt. 2Expt. 1
40434 ± 8203b 8996 ± 2857Control
c, d 4778 ± 1163 (47)e2042 ± 106 (94.9)H238 CM
a 3 x 105 effector and mitomycin C target cells were 
incubated for 5 days with a 5 hour pulse label. 
b Values represent mean dpms of quadruplet cultures. 
c % inhibited (normal dpm - test dpm)/control dpm x 100. 
d P < 0.0003 
e P < 0.02
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TABLE III
Effect of H238-GI on IL-2 production by lectin-induced splenocytes
Units IL-2




8.5 (10)bCon A + H238 GI
2.8 (63)bCon A + Hep-Seph.
fraction 20








b, c 6127f119692121431 (40)0.48 mg/mlHep-Seph 
fraction 20
145586 (28)d 112261 63130.24 mg/ml
144610 (29)e 103524 66450.12 mg/ml
a Values represent mean dpms of triplicate cultures 
k % inhibition 
c P < 0.001 
d P < 0.003 
e P < 0.004 
f P < 0.07
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TABLE V
Effect of H238-GI on H238 cells
3[ H]-TdR incorporation
Expt. 2bExpt. la
2% FCS 10% FCS1% FCSAddition
4983 ± 715c 4093 ± 407 19688 ± 5895Buffer
14665 ± 3995d4326 ± 13664318 ± 844H238-CM
a 2 x 10A cells were cultured for 24 hours in 0.5 ml serum- 
free before effectors were added. 18 hours later cultures 
were pulsed for 5 hours.
b 2 x 104 cells were cultured for 24 hours in 0.5 ml media 
with 0.5% serum before effectors were added. 18 hours 
later cultures were pulsed for 5 hours. 
c Values represent mean dpms ± SE of six cultures 
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Serum-free H238-CM (10Affinity chromatography of H238-CM.Figure 1.
mg total protein) concentrated 20 fold by ultrafiltration was passed 
through an FPLC column of heparin-sepharose equilibrated with 10 mM
TwoColumn gradient was from 0.1-3.0 M NaCl.
Spleen cell inhibitory 
activity was assayed by culturing splenocytes (2 x 105 in 0.2 ml) for 40 
hours with Con A (2.5 pg/ml) in RPMI 1640 medium containing 0.1 ml of a 
1:10 dilution of each fraction. Proliferation was determined by [3H]- 
TdR incorporation. Values represent the mean % inhibition of three 
experiments.
100 mM NaCl.Tris,
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Figure 2. The effect of H238-GI on the macromolecular biosynthesis of 
lectin-stimulated splenocytes. In panel A the inhibitory activity of 
H238-GI for Con A-induced (2.5 /ig/ml) spleen cells (2 x 105 in 0.2 ml) 
tested in a dose-response assay (0.12-0.48 /zg/ml).
DNA was measured by the incorporation [3H]-TdR. 
transcription was measured by [3H]-uridine incorporation. In panel C an 
H238-GI dose-response assay for protein synthesis was measured by [ H]-
Values represent the mean ± SD of the total
Proliferation ofwas
In Panel B RNA
leucine incorporation, 
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Pretreatment
on lectin-stimulatedeffect of H238-GI pretreatment
In panel A splenocytes (2 x 10^ in 0.2 ml)
Figure 3. The 
splenocyte blastogenesis. 
were cultured for 3 hours with Con A (2.5 ng/ml final concentration) in 
the presence (open box) or absence (hatched box) of H238-GI (0.48 /xg/ml) 
at which time effectors were removed. The resulting proliferation was 
measured by [3H]-TdR incorporation at 48 hours post-treatment. At 19 
hours post-treatment one set of cultures received additional H238-GI 
(0.48 /xg/ml) (cross-hatched box). In panel B splenocytes were again 
pretreated for 3 hours with Con A (2.5 /xg/ml) in the presence (open box) 
or absence (hatched box) of H238-GI (0.48 /xg/ml). At 19 hours post­
treatment one set of cultures received additional H238-GI (0.48 /xg/ml) 
(cross-hatched box). Values represent the mean ± SD of the total dpm's 
of three experiments.
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Effect of H238-GI on IL-2-induced proliferation of CTLL-1 
Panel A, CTLL-1 cells (1 x 104 in 0.2 ml) were cultured with IL- 
2 (250 units/ml) in the presence (open box) or absence (hatched box) of 
H238-GI (0.48 fig/ml). Proliferation was measured at 18 hours by [3H]-
Total [3H]-TdR incorporation is expressed as mean % 





Sd of three experiments.
deprived of IL-2 for 24 hours before addition of effectors.
IL-2 (250 units/ml) was added in the presence (open box) or absence 
(hatched box) of H238-GI (0.48 /xg/ml). 
and 40 hours thereafter.
Cultures were terminated at 20
Total [3H]-TdR incorporation is expressed as
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Figure 5. Effect of H238-GI on lectin-induced c-myc proto-oncogene 
expression. Splenocytes (1 x 107 in 10 ml) were cultured with Con A 
(2.5 /ig/ml) in the presence (0) or absence (0) of H238-GI (0.19 /zg/ml) . 
Cytoplasmic RNA from cultures was extracted and measured at the 
indicated times by dot blot analysis using a c-myc DNA probe. Values 
relative OD units determined by densitometric scanning ofrepresent
autoradiographs from the dot blot analysis.
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DISCUSSION
In this study we report the immune inhibitory activity of a
nondialyzable factor (H238-GI) produced by the H238 HSV-2-transformed
embryonic fibroblast tumor cell line. It strikingly inhibitsmouse
splenocyte proliferation assays designed immunologicto measure
competence, lectin-induced stimulation, allogenic IL-2MLR, and
It also inhibits the IL-2production of lectin-stimulated splenocytes.
dependent proliferation of CTLL-1 cells but at a fraction of the level
of inhibition seen in Gq splenocytes. 
reversible and can exert its inhibitory effect when present for only the
The inhibition of splenocytes is
last 24 hours of culture. It acts in a dose-dependent manner inhibiting
3DNA synthesis, as measured by [ H]-TdR incorporation, while having no 
quantitative effect on the RNA and protein synthesis of lectin-
Qualitatively, in a kinetic study H238 wasstimulated splenocytes.
The c-mycfound to inhibit the expression of the c-myc proto-oncogene.
gene is an early response gene expressed rapidly after lectin-
stimulation of lymphocytes (23-26) and has been implicated to be
associated with DNA polymerase activity (43).
The inhibition of the lectin stimulation of splenocytes is a common
characteristic of tumor cell-derived immune inhibitory factors (10-14).
In addition to the inhibition of an assay of lymphocyte function it
provides a convenient method with which to detect the antiproliferative
We tested two different lectins, PHA and Con A, that bind tofactors.
different sugar residues, N-acetyl-glucosamine and mannose/galactose
respectively, to rule out selective inhibition of lectin by direct
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interaction with the lectin mitogen. We observed no specific difference
in the inhibitory activity of the H238-GI with each lectin. We then
tested a more specific proliferative response, allogenic MLR, and found
that this response was almost completely blocked. We did not test for a
more qualitative response, such as cytotoxic lymphocytes, because we
were interested in the antiproliferative activity of the H238-GI.
To rule out inhibition due to a toxic effect of the H238-GI on the
splenocytes, we measured the DNA, RNA, and protein synthesis in a dose
We observed a dose-dependent specific inhibition of DNAresponse assay.
synthesis but no quantitative inhibition of RNA and protein synthesis.
This indicated that the H238-GI was not toxic and selectively inhibited
DNA synthesis.
We looked at the effect of H238-GI on the ability of lectin-
stimulated splenocytes to produce IL-2. 11-2 production was inhibited
at a level that correlates with the inhibition of proliferation.
Measurement of IL-2 production has a direct bearing on the clonal
proliferation of the responding cells, and a decrease in its production
would indicate a possible mechanism of action. In the lymphocyte
proliferation model two possible sites of action for the H238-GI present
IL-2 regulates thethemselves, Gq/G-^ transition and G^-S progression.
G-^-S progression.
IL-2 stimulated proliferation utilizing an IL-2 dependent cell line,
Based on this we looked at the H238-GI inhibition of
We found a slight inhibition that did not correlate with theCTLL-1.
inhibition of lectin-induced proliferation. We speculated that what was
happening in this experiment was not G^-S progression inhibition but 
selective inhibition of the small percentage of cells cycling through
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To test this hypothesis wethe early G-^ phase during the 18 hour assay, 
removed IL-2 from the CTLL-1 cells for 24 hours in an attempt to
synchronize the cells in the Gq state before addition of recombinant IL-
We found an increased inhibition of the IL-2-stimulated2.
proliferation in the presence of H238-GI that lasted throughout the
period of observation indicating a probable site of action on the Gq/G-^
transition.
We decided to look for a marker of Gq/G-^ transition to determine the
The c-myceffect of H238-GI on this site of the proliferation cycle.
proto-oncogene is a very good marker of Gq/G-^ transition that has been 
associated with the regulation of DNA polymerase (43) but this is still
an unsubstantiated observation (46) . It is a nuclear proto-oncogene
proliferationdifferentially regulated duringthat is or
Its transcription is up-regulated immediately duringdifferentiation.
(23-26) down-regulated withandlectin-induced proliferation
We found that thedifferentiation of hematopoietic tissues (44,45).
H238-GI inhibits c-myc transcription by 30% at 3 hours which correlates
well with the inhibition of lectin-stimulated proliferation observed for
The qualitative inhibitionthe dose of H238-GI used in this experiment.
of the c-myc gene transcription by the H238-GI represents a specific
site for the inhibitory action within the proliferation cycle. It
allows for the recognization by immunologically competent cells but
The observation of an apparentinhibits their clonal proliferation.
late effect by H238-GI when added to the cultures at 19 hours post­
stimulation probably represents an inhibition of further rounds of DNA
synthesis and not an action on a late G-^-S event. The decrease in IL-2
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production also correlates well with the inhibition of c-myc gene
IL-2 gene transcription occurs with the same kinetics astranscription.
c-myc transcription and may be affected in a similar fashion.
Immune inhibitory factors have been reported from a variety of in
vivo and in vitro sources (10-18). Among these are several with
characteristics similar to the H238-GI; the tumor extracts of human
(16) and mouse K-1735 cells (11) and the CM's from humanesophagus
myeloma U937 cells (13) and the HT29 human colon carcinoma. These
factors inhibit mitogen stimulation, IL-2 production, and MLR. They do
The U937 cells warrantnot inhibit IL-2-dependent CTLL-2 proliferation.
a closer look; they produce their inhibitory factor when induced to
It has also been demonstrateddifferentiate with phorbol esters (13).
that phorbol ester treatment of U937 cells causes them to differentiate
under the regulation of an autologous factor, interferon /3 (IFN /3) (44) . 
IFN ft also has similar inhibitory activities for lymphoproliferative
responses that these tumor-derived factors possess (47) . IFN P has also
been shown to inhibit c-myc transcription in PDGF treated fibroblasts
(48) and to induce Gq/G-^ arrest in hematopoietic cells associated with a
The problem of pleomorphic molecularreduction in c-myc expression.
in the tumor-derived inhibitory factors may parallel themass seen
diversity seen during the early work on IFN purification. It is
possible that these tumor factors are related to IFN and that the
significance may be that the tumors that produce these factors have lost
their ability to respond as have the H238 cells: thus the over­
production of a normal homeostatic may occur.
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A factor with characteristics similar to the H238-GI would have a
By inhibiting cellsignificant impact on the in vivo immune response.
proliferation without a toxic effect on the responding cells it would
allow for the infiltration into a tumor of immunologically competent
lymphocytes but would inhibit their clonal proliferation, thus allowing
It would explain thethe tumor to escape an effective immune response.
finding of immunologically effective cells within a tumor by Rosenberg
and associates (50) and why these cells are effective therapeutically
when clonally expanded in vitro and reintroduced into the host. Also
the increased therapeutic efficacy of biological response modifiers
(BRM) given intralesionally as opposed to systemically could have their
effect on the cells inhibited by this type of factor. The in vivo
validity of this factor remains to be proven but the isolation of
several factor with similar characteristics to the H238-GI from tumors
of mesenchymal origin lends support to this type of antiproliferative
If these inhibitory factors are typical of tumors of mesenchymalmodel.
tissue they would present an inviting target for therapeutic agents used
in combination with BRMs and lymphokine-activated cytotoxic cells.
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The conditioned tissue culture medium from the H238 tumor cell line
contains nondialyzable growth regulatory factors that can be divided by
their positive, mitogenic, or negative inhibitory, activities. The
3
positive factor(s) stimulated [ H]-TdR incorporation into chick embryo
[3H]-TdR 
These
calvarial cells while the negative activity inhibited the
incorporation into lectin-stimulated mouse splenocytes.
activities could be separated and partially purified by FPLC heparin-
Upon fractionation the positivesepharose affinity chromatography.
activity was separated unto three peaks containing mitogenic activity
whereas the negative activity was confined in one peak of activity.
Characterization of the three positive growth regulatory factors
revealed a similarity to previously described polypeptide growth
Peak A possessed the ability to support the anchorage-factors.
independent growth of EGF-treated fibroblasts which is the classical
Peak B had similar biochemical properties to PDGFassay for TGF-y3 (48).
Peak C displaced bFGF in an RIA assay and binds to heparin-(80,81).
sepharose with an affinity only observed with FGF-like activities (105).
The inhibitory activity, Peak D, coeluted with Peak B of the positive
It is distinct from the PDGF-like activity but itsgrowth factors.
It possesses some similar activities tolineage is as yet unknown.
interferon (54) but we have not been able to demonstrate a direct
relationship. It inhibits a variety of immunological assays designed to
test immunologic functions: lectin-stimulation, mixed lymphocyte
reaction, and production of IL-2.
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In the following paragraphs we will discuss the interactions of these
growth regulatory factors with the tumor itself, autocrine, and with the
host, paracrine, in an attempt to develop a plausible model for tumor
We will discuss this in light of what has been reportedestablishment.
about the activities of the growth regulatory factors isolated from the
conditioned medium of the H238 tumor cell line.
Autocrine
The autocrine hypothesis (65) for the autologous production and
response to growth factors by the tumor cells is an intuitively
acceptable mechanism by which tumors may achieve relaxed control of the
proliferation cycle. With the demonstration of tumor cell production of
growth factors and the presence of receptors on the same tumor cells for
the factors, this has become accepted dogma.
PDGF, bFGF, and TGF-/3 are all mitogenic for fibroblasts (80,105.112).
PDGF and bFGF act directly (80,105) while TGF-/3 acts indirectly by
PDGF also activates a negative regulatory factor,inducing PDGF (112).
interferon, as part of its mitogenic action (165). This negative
activity is believed to act in the normal homeostasis of the cells'
PDGF and bFGF have been associated with transformationproliferation.
(17,72).
For the H238 autocrine model all three growth factors are capable of
The demonstration of a factormitogenic stimulation of the tumor cells.
that resembles a bFGF-like activity is somewhat controversial. It has
been reported for other tumor cell lines, but when the gene for bFGF was
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cloned, it was found not to possess a signal peptide and therefore was
A determination of any possible causalbelieved to be cell-associated.
relationship of bFGF secretion and herpes virus-induced transformation
needs to be followed up in light of the transforming potential of FGF
PDGF and TGF-/3 are produced by many tumors of mesenchymal origin(72).
(67,48) and may not represent a specific target for the HSV-2
Their continued production may represent antransformation event.
escape from the negative regulation of the inhibitory factor. The
inhibitory factor is not active on the H238 cells; if it is similar to
interferon, then the production of PDGF, TGF-^, and the inhibitory
factor may represent a deregulated self-perpetuating loop, where TGF-/3
induces PDGF which then induces inhibitory activity and TGF-/? and so on.
ability to respond to the inhibitoryThe loss of the H238 cells'
activity may also be a target for HSV-2 induced transformation.
Paracrine
It has long been known that transplantable tumor development requires
its interaction with host stroma if the tumor is to survive (166) . It
was believed that this interaction is directed by the tumor which
produced factor(s) that cause the chemotactic migration of fibroblasts
These host stroma cellsand vascular endothelial cells into the tumor.
are necessary for support and nutrition of the growing tumor. With the
discovery of growth factors and that tumor cells can produce some of
these factors, it has been possible to support the earlier hypothesis.
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PDGF is a major mitogen for mesenchymal cells (15,80). It induces
the chemotaxis of (82) , the production of IGFs by (167) , and the
It also induces the chemotaxis ofproliferation of fibroblasts (80).
TGF-£ is a potent angiogenic factor causing thesmooth muscles (82).
chemotaxis and differentiation of vascular endothelial cells (107). As
stated above TGF-fl induces PDGF production in fibroblasts (112). FGF is
a major mitogen for vascular endothelial cells and potent angiogenic
factor (105).
For the H238 paracrine model these factors could interact with host
First, H238 is a transformed cell ofstroma to support tumor growth.
fibroblastic origin, it probably requires insulin-like growth factors
PDGF would stimulate the(IGF) to complete its proliferation cycle.
surrounding fibroblasts to migrate into the tumor and to produce this
necessary growth factor insuring an adequate supply of IGF's for growth
The migrating fibroblasts would also provide support forof the tumor.
PDGF, FGF, and IGF-/? would act together to inducethe tumor.
angiogenesis necessary to provide nutrition to the tumor. PDGF and TGF-
P would induce the migration of smooth muscle and vascular endothelial
FGF would support the necessary proliferation these vascularcells.
Once they have migratedendothelial cells would require to migrate.
into the tumor TGF-/? would induce them to differentiate into tubular
In this manner these growth factors would ensure the tumorcapillaries.
growth and nutrition.
The paracrine action of the inhibitory factor appears to help the
tumor cell escape the immunological defense mechanisms. It acts by
inhibiting the proliferation of immunocompetent cells. In the in vivo
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environment a factor like the H238-GI would allow for the infiltration
into the tumor of immune cells capable of mounting a response but it
The inability of a clonalwould inhibit their proliferation.
proliferative response by these immunocompetent cells would allow the
tumor cells immunologically unobstructed growth. This type of
inhibition without toxic effect on the immune cells may be the reason
why Rosenberg and associates (128) have been able to demonstrate tumor
infiltrating lymphocytes and use them for successful therapy.
Future
This model of autocrine and paracrine interaction for tumor growth is
The possible genetic mutations in the growth factor genestestable.
induced by the inactive HSV-2 virus needs to be examined. These
mutations may be as simple as multiplication and/or rearrangement of the
growth factor genes although this is doubtful for PDGF and TGF-/3. The
HSV-2 insertion element could possibly act through an insertion-promoter
mechanism allowing the unregulated transcription of the growth, factor
These are relatively simple mechanisms that can be tested bygene.
If these are not observed, it becomes a muchsouthern blot analysis.
more formidable task to determine the mechanism.
The possibility of an autocrine mechanism for tumor proliferation
would be strengthened by the demonstration of receptors for the specific
This could be done in a receptor bindingfactors on the tumor cells.
assay using radiolabeled purified growth factors. It is sometimes
difficult to demonstrate receptors for PDGF in transformed cells because
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the cells undergo a down-regulation in detectable receptors after
This is believed to be due to the binding of thetransformation (67).
In the case of the inhibitory factor, twoautologous PDGF.
possibilities involving the- lack of a functional receptor would need to
be looked at: one, complete lack of receptor expression, and two, the
inability of the receptor to transmit the correct intracellular signal.
For the paracrine model the functions of PDGF, FGF, and TGF-/3 are
The determination of the in vivo nature of thefairly well documented.
The in vivo validity ofinhibitory factor needs to be established.
tumor secreted immunosuppressive factors still remains to be proven.
But the isolation and characterization of these factors derived from in
vitro tumor cell lines is a clue to the actions of these cells in vivo. ■
If immunosuppressive factors are real they may provide a significant
site that could be attacked successfully by the therapeutic use of
monoclonal antibodies and biological response modifiers.
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